Healthcare entity
Of the tracked stories, 2 of 4 also mention World Health Organization (WHO), the most common co-covered peer. Each story carries 34.5 original sources on average, compared with 4 for the broader beat in this window. At 7.3, the average consequence score sits above the same-window beat average of 6.1.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 25 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 4 also mention World Health Organization (WHO), the most common co-covered peer. Each story carries 34.5 original sources on average, compared with 4 for the broader beat in this window. At 7.3, the average consequence score sits above the same-window beat average of 6.1. The 135-day window averages about 0.2 stories each week. The clearest coverage concentration is market-trends: 2 of 4 stories, with the rest divided among 1 other category. This profile follows 4 Healthcare stories mentioning Sanofi across the period from March 4, 2026 to July 16, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 658 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sanofi. Shared-story counts are live from our verified record — not editorial picks.
Rollout Milestone
Acoziborole enters the final stages of regulatory rollout for endemic regions.
Trial Results
Phase 2/3 clinical trial results for Acoziborole show high efficacy.
Fexinidazole Approval
First all-oral 10-day treatment for sleeping sickness is approved.
Research Begins
DNDi starts screening compounds for a single-dose HAT treatment.
The FDA approved the first oral PCSK9 inhibitor, Lipfendra, demonstrating a 59% LDL reduction in trials. The pill form removes injection barriers and is priced lower than existing injectables, potentially improving adherence and access for patients with high cholesterol.
The introduction of Acoziborole, a single-dose oral medication, marks a pivotal shift in the global fight against Human African Trypanosomiasis. This breakthrough treatment simplifies complex therapeutic regimens, potentially enabling the total elimination of the disease by 2030.
Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Source: abc11.com · abc7ny.com
The CDC has issued a series of travel notices for popular international tourist destinations following a spike in polio detections. The move signals a shift in global health security, requiring travelers to verify immunization status and potentially seek adult boosters before departure.
Source: newstalk1230.iheart.com · 600wrec.iheart.com
Sanofi is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
